SAN DIEGO -- (BUSINESS WIRE) -- Illumina, Inc. (NASDAQ:ILMN) today launched an advanced high-throughput screening (HTS) array format that significantly increases the number of samples that can be processed on the Infinium® BeadChip family of genotyping arrays. Illumina’s Infinium assay leverages proven chemistries on a new 24-sample HTS BeadChip that supports up to 750,000 markers per sample and increases scanning capacity by up to three-fold.
“We're excited to introduce this new array format as it enables our customers to perform larger, more powerful studies that enhance discovery,” said Christian Henry, Senior Vice President and General Manager, Genomic Solutions at Illumina. “The 24-sample HTS BeadChip strengthens Illumina’s leading position in the array market and further demonstrates our ability to continue innovation on our array platform, providing customers with high-quality, high-throughput genotyping solutions. The new format allows us to offer breakthrough pricing per sample which is important to enable direct-to-consumer, biobanking, basic research, and agricultural applications.”
Illumina’s HumanOmniExpress BeadChip will be the first standard array available on the 24-sample HTS BeadChip, part of a portfolio of whole-genome genotyping arrays with new affordable pricing. This powerful array contains approximately 700,000 markers including the latest updates from the 1,000 Genomes Project strategically selected to capture the greatest amount of common SNP variation and drive the discovery of novel associations with traits and disease. It can also include up to 50,000 custom markers, making it ideal for those interested in large genotyping studies such as core labs, genome centers, and biobanks.
“We are very happy with the quality of data we obtained using the Illumina Infinium technologies,” said Mark Kelleher, Director of Laboratory Operations at 23andMe. “We are now very excited to deploy the higher-throughput BeadChips to enhance our ability to process larger volumes of samples as we expand our customer base.”
The first consortium-designed array on the 24-sample HTS BeadChip will leverage the new format and affordable pricing to help researchers explore the association between variants to five common cancers – breast, ovarian, colon, lung, and prostate. The Infinium OncoArray-530K BeadChip (OncoArray), designed in collaboration with leading experts from the OncoArray consortium and enabled by the development of the 24-sample HTS BeadChip, delivers the core content found on Illumina’s Infinium HumanCore array along with approximately 250,000 additional candidate variants identified by OncoArray consortium members and room for 100,000 markers of semi-custom content. The consortium members are planning a study of unprecedented size which will use the OncoArray to analyze over 425,000 samples and detect subtle associations within and between cancer types.
“The OncoArray is a major new tool for providing future insights into the relationship between genetic variants and cancer predisposition,” said Doug Easton, Professor of Genetic Epidemiology at Strangeways Research Laboratory, University of Cambridge, and a leader of the OncoArray consortium. “It was great working with Illumina to develop the OncoArray. The array contains the custom content we need, in a high-throughput format that will make our large-scale study feasible and should lead to a whole new wave of discoveries.”
The HumanOmniExpress BeadChip is now shipping in the 24-sample HTS format. The OncoArray, iSelect, HumanCoreExome, and HumanCore BeadChips in the 24-sample HTS format are expected to begin shipping in Q1 2014. For more information, please visit http://www.illumina.com/infiniumHTS.
Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.
This release contains forward looking statements that involve risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements we make regarding the expected shipping date for the OncoArray, iSelect, HumanCoreExome, and HumanCore BeadChips in the 24-sample HTS format and the planned consortium study. Important factors that could cause actual results to differ materially from those in any forward-looking statements include challenges inherent in developing, manufacturing, and launching new products and services and the other factors that are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.